In the recent, Jubilee Issue of Leukemia (Dec 2025), the work of the EuroClonality consortium is brought into the spotlight. In an Editorial, Andreas Hochhaus and Robert Peter Gale reflect on 40 years of scientific publications and highlight fourteen of the most cited and influential articles in the magazine.

Measurable Residual Disease (MRD) is a key factor in modern hemato-oncology. By detecting tiny numbers of remaining cancer cells after treatment — often missed by standard tests — MRD helps predict relapse and guides decisions on treatment intensity.

ESLHO has formally adopted the organization of the EQA schemes of EuroClonality, EuroFlow, and EuroMRD under the ESLHO EQA program. Historically, these three consortia each organized and offered their EQA programs independently.